| GPS |
GPS-0. Nationwide surveys among the general population: bibliographic references
|
| GPS |
GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
Part (i) Lifetime prevalence all adults (percentage)
|
| GPS |
GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
Part (ii) Survey methods
|
| GPS |
GPS-2. Lifetime prevalence of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population
|
| GPS |
GPS-3. Last year prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
|
| GPS |
GPS-4. Last year prevalence of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population
|
| GPS |
GPS-5. Last month prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
|
| GPS |
GPS-6. Last month prevalence of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population
|
| GPS |
GPS-7. Last month prevalence and frequency of use of cannabis among all adults (aged 15 to 64 years old) and young adults (aged 15 to 34 years old) in nationwide surveys among the general population
Part(i) Last month prevalence (percentage)
|
| GPS |
GPS-7. Last month prevalence and frequency of use of cannabis among all adults (aged 15 to 64 years old) and young adults (aged 15 to 34 years old) in nationwide surveys among the general population
Part(ii) Frequency of use among all users in last month (percentage)
|
| GPS |
GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
Part (i) Lifetime prevalence all adults (percentage): last survey available for each Member State
|
| GPS |
GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population
Part (ii) Survey methods: last survey available for each Member State
|
| GPS |
GPS-9. Lifetime prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
|
| GPS |
GPS-10. Last year prevalence (percentage) of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
|
| GPS |
GPS-11. Last year prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
|
| GPS |
GPS-12. Last month prevalence (percentage) of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
|
| GPS |
GPS-13. Last month prevalence (percentage) of drug use among young adults (aged 15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
|
| GPS |
GPS-14. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
|
| GPS |
GPS-15. Last year prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
|
| GPS |
GPS-16. Last month prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population
|
| GPS |
GPS-17. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State
|
| GPS |
GPS-18. Last year prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State
|
| GPS |
GPS-19. Last month prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population: last survey available for each Member State
|
| GPS |
GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (i) United Kingdom
|
| GPS |
GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (ii) Germany
|
| GPS |
GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (iii) Spain
|
| GPS |
GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (iv) France
|
| GPS |
GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (v) Italy
|
| GPS |
GPS-20. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (vi) Netherlands
|
| GPS |
GPS-21. Methodological information for nation-wide surveys among the general population
|
| GPS |
GPS-1. Last year prevalence of cannabis among all adults (aged 15 to 64 years old), young adults (aged 15 to 34 years old) and for the 15 to 24 years old age group, measured by national population surveys
|
| GPS |
GPS-2. Continuation rates of cannabis (last year and last month use among lifetime users) in the general population, as measured by national surveys
|
| GPS |
GPS-3. Last month prevalence of cannabis among the age group of 15 to 24 years, measured by national surveys
|
| GPS |
GPS-4. Trends in last year prevalence of cannabis among young adults (aged 15 to 34), measured by national surveys
|
| GPS |
GPS-5. Last year prevalence of amphetamines among young adults, 15 to 34 and 15 to 24, measured by population surveys
|
| GPS |
GPS-6. Last year prevalence of amphetamines among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
|
| GPS |
GPS-7. Last month prevalence of cannabis among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group
|
| GPS |
GPS-8. Trends in last year use of amphetamines among young adults (aged 15 to 34), measured by population surveys
|
| GPS |
GPS-9. Last year prevalence of ecstasy among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group
|
| GPS |
GPS-10. Last year prevalence of cannabis by age group in United Kingdom, measured by national population surveys
|
| GPS |
GPS-11. Continuation rates of ecstasy (last year and last month use among lifetime users) in the general population, as measured by national surveys
|
| GPS |
GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys – last survey available
Part (i) Last year prevalence in some of the EU-15 Member States
|
| GPS |
GPS-13. Last year prevalence of cocaine among all young adults (aged 15 to 34 ) by gender, measured by national surveys
|
| GPS |
GPS-14. Trends in last year prevalence of cocaine among young adults (aged 15 to 34), measured by population surveys
|
| GPS |
GPS-15. Last year prevalence of cocaine use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
|
| GPS |
GPS-16. Continuation rates of cocaine (last year and last month use among lifetime users) in the general population, measured by national surveys
|
| GPS |
GPS-17. Last year prevalence of amphetamines, ecstasy and cocaine among young adults (15 to 34 years)
|
| GPS |
GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34)
Part (i) Cannabis use – lifetime experience, last year and last month prevalence
|
| GPS |
GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34)
Part (ii) Cocaine, amphetamines and ecstasy use – lifetime experience, last year and last month prevalence
|
| GPS |
GPS-19. Comparison of drug use prevalence during last year by different user groups in the general population aged 15 to 34 – data for Spain, 1999
|
| GPS |
GPS-20. Lifetime and last year prevalence of cocaine use among young adults (aged 15 to 34) in Europe, Canada, Australia and the USA - last survey available for each country
|
| GPS |
GPS-21. Trends in last year prevalence of ecstasy among young adults (aged 15 to 34), measured by population surveys
|
| GPS |
GPS-22. Continuation rates of amphetamines (last year and last month use among lifetime users) in the general population, as measured by national surveys
|
| GPS |
GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
|
| GPS |
GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys – last survey available
Part (ii) Last year prevalence in some new EU Member States
|
